[Clinical efficacy of sulbactam/cefoperazone for the treatment of geriatric patients with respiratory tract infections].

Abstract

We performed clinical studies on sulbactam/cefoperazone (SBT/CPZ) for the treatment of geriatric patients with respiratory tract infections. Seven patients with pneumonia, 7 with acute bronchitis, 6 with chronic respiratory tract infections were treated with SBT/CPZ. The patients were administered with a daily dose of 2.0 g or 4.0 g for 4-14 days. The clinical responses were excellent in 3, good in 13, fair in 3, and poor in 1 patients. The efficacy rate was 80.0%. No side effects were observed in any patients, but elevations of GOT, GPT were observed in two cases. Causative organisms were E. coli (2 strains), P. aeruginosa (2), MSSA (1), MRSA (1), S. pneumoniae (1), H. influenzae (1), K. oxytoca (1), and E. aerogenes (1). The bacteriological effect rate was 60%. One strain of MRSA and one of two strains of P. aeruginosa persisted in 2 patients.

• Authors: K Takaki, M Umeno, M Tanaka, S Harashima, T Takeda, K Okada, Y Sawae
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 48 Issue 7 Pg. 942-8 (Jul 1995) ISSN: 0368-2781 [Print] Japan
• PMID: 7563587 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Cephalosporins
• Cefoperazone
• Sulbactam

Topics

• Aged
• Aged, 80 and over
• Anti-Bacterial Agents (administration & dosage)
• Cefoperazone (administration & dosage)
• Cephalosporins (administration & dosage)
• Drug Therapy, Combination (administration & dosage)
• Female
• Humans
• Infusions, Intravenous
• Male
• Respiratory Tract Infections (drug therapy, microbiology)
• Sulbactam (administration & dosage)